Ginkgo Bioworks Reports Strong Q1 2025 Growth

Ginkgo Bioworks Holdings, Inc. ( (DNA) ) has released its Q1 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors.

Ginkgo Bioworks Holdings, Inc. is a leader in cell programming and biosecurity, offering comprehensive services across various sectors such as food, agriculture, pharmaceuticals, and specialty chemicals. The company is recognized for its innovative approach to biosecurity and cell engineering.

In the first quarter of 2025, Ginkgo Bioworks reported a total revenue of $48 million, marking a 27% increase from the previous year. This growth was primarily driven by a $7 million non-cash revenue from the release of deferred revenue. Excluding this, the revenue stood at $41 million, up by 8%. The company also highlighted its successful restructuring efforts aimed at achieving significant cost savings.

Key financial metrics included a GAAP net loss of $91 million, a notable improvement from the $166 million loss in the previous year. The adjusted EBITDA also showed progress, improving to a loss of $47 million from $117 million. The company’s cash and marketable securities balance was reported at $517 million, indicating a strong liquidity position.

Strategically, Ginkgo Bioworks secured a $29 million contract with ARPA-H to develop distributed manufacturing systems for essential medicines. The company is also making strides in its Datapoints and Automation offerings, with new deals and opportunities emerging. Ginkgo is on track to achieve its cost reduction target of $250 million by the third quarter of 2025.

Looking ahead, Ginkgo Bioworks remains focused on reaching adjusted EBITDA breakeven by the end of 2026. The company is well-positioned to capitalize on emerging opportunities in biotechnology and biosecurity, driven by its robust platform and strategic partnerships.